Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | PAH | P00439 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12559341 | 1.00 | HSD17B10 (0.39) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL22971947 | 1.00 | HSD17B10 (0.39) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL31673801 | 1.00 | HSD17B10 (0.39) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL21009255 | 0.78 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL31026287 | 0.78 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL258405 | 0.78 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL29365035 | 0.78 | HSD17B10 (0.63) | HSD17B10CASP7KDM4EMAPTBLM | |
| SCHEMBL1533830 | 0.78 | — | — | |
| Sepiapterin SCHEMBL258399 | 0.77 | CASP7 (0.65) | HSD17B10CASP7KDM4EMAPTBLM | |
| Sepiapterin SCHEMBL27081912 | 0.77 | CASP7 (0.65) | HSD17B10CASP7KDM4EMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2025054048-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2025-03-13 | — | — | WO | claimed |
| EP-4440342-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| EP-4401745-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES | MarvelBiome, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| CN-118265532-A | Methods and uses of microbiome compositions, components or metabolites for treating neurodegenerative diseases | 奇迹生物公司 | 2024-06-28 | — | — | CN | claimed |
| WO-2024084421-A1 | TREATMENT OF VASCULAR DISEASES ASSOCIATED WITH GENETIC VARIATIONS IN ACTA2 | QRGENETICS LTD. (IL) | 2024-04-25 | — | — | WO | claimed |
| US-20240124850-A1 | Auxotrophic Cells for Virus Production and Compositions and Methods of Making | SHAPE THERAPEUTICS INC. | 2024-04-18 | — | — | US | claimed |
| WO-2024058984-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2024-03-21 | — | — | WO | claimed |
| EP-4304557-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | MarvelBiome, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| US-20150038522-A1 | COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER | KEIO UNIVERSITY (JP) | 2015-02-05 | — | — | US | claimed |
| EP-2818870-A1 | COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER | Keio University (JP) | 2014-12-31 | — | — | EP | claimed |
| US-20140249152-A1 | TREATMENT FOR GASTROPARESIS USING SEPIAPTERIN | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-04 | — | — | US | claimed |
| US-20110098306-A1 | Uses of tetrahydrobiopterin, sepiapterin and derivatives thereof | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE | 2011-04-28 | — | — | US | claimed |
| US-7863275-B2 | Uses of tetrahydrobiopterin and derivatives thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-04 | — | — | US | claimed |
| WO-2008054693-A9 | USES OF TETRAHYDROBIOPTERIN AND DERIVATIVES THEREOF | UNIV TEXAS (US) | 2008-09-04 | — | — | WO | claimed |
| US-20080207579-A1 | Uses of tetrahydrobiopterin and derivatives thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2008-08-28 | — | — | US | claimed |
| WO-2008054693-A2 | USES OF TETRAHYDROBIOPTERIN AND DERIVATIVES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-08 | — | — | WO | claimed |
| US-20060188492-A1 | Topical management of ocular and periocular conditions | CHRONORX LLC, AN ALASKA LIMITED LIABILITY COMPANY (US) | 2006-08-24 | — | — | US | claimed |
| US-5606020-A | 6 (R)-l-erythro-5,6,7,8-tetrahydrobiopterin receptor | SUNTORY LIMITED (JP) | 1997-02-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | HSD17B10 229/4885CASP7 3978/4885KDM4E 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.